AGENDA

8:00 a.m.  Opening Introductions
Bruce Psaty, MD, PhD, MPH, Science Board Chair

8:10 a.m.  Conflict of Interest
Rakesh Raghuvanshi, MPH, Designated Federal Officer, Science Board, FDA

8:15 a.m.  Chief Scientist’s Remarks
Luciana Borio, MD, Acting Chief Scientist, FDA

8:20 a.m.  Final Report – CERSI Program Evaluation Subcommittee
Scott Steele, PhD, Subcommittee Chair

8:40 a.m.  Commissioner’s Remarks
Robert Califf, MD, Commissioner of Food and Drugs, FDA

8:45 a.m.  Introductory Remarks: The Larger Landscape of Pain Management – Seeking Balance
Janet Woodcock, MD, Director, Center for Drug Evaluation and Research (CDER), FDA

9:15 a.m.  The Modern Science of Pain
Daniel Alford, MD, MPH, Director, Safe and Competent Opioid Prescribing Education (SCOPE of Pain) Program, Boston University School of Medicine

9:45 a.m. Break

10:00 a.m.  The Development of Treatments for Pain
Daniel Clauw, MD, Professor, Pain Management, Anesthesiology, University of Michigan School of Medicine

10:30 a.m.  The Modern Science of Addiction
Mary Jeanne Kreek, MD, Patrick E & Beatrice M Haggerty Professor, Laboratory of the Biology of Addictive Diseases, Rockefeller University

11:00 a.m. Discussion

11:45 a.m.  Lunch (on your own)

12:30 p.m.  FDA and Policies Related to Development and Use of Opioids to Treat Pain
Douglas Throckmorton, MD, Deputy Director for Regulatory Programs, CDER, FDA

1:00 p.m.  Challenge of Developing New Pain Medicines – Developing Novel Analgesics and Abuse-Deterrent Opioid Formulations
Sharon Hertz, MD, Division of Anesthesia, Analgesia and Addiction Products, Office of New Drugs, CDER, FDA

1:30 p.m.  Challenges in Assessing Real World Use and Abuse of Opioids
Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, CDER, FDA

2:00 p.m.  Break

2:15 p.m.  Open Public Hearing

3:50 p.m.  Discussion

5:00 p.m.  Closing Comments
Bruce Psaty, MD, PhD, MPH, Science Board Chair